Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID RPD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID RPD.
AXID vs PEPCID RPD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist